Kari Salokas

Kari Salokas

Auto-generated profile, based on publicly available information

Kari Salokas

Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXiaonan Liu
Xiaonan Liu
KSKari Salokas
Kari Salokas
FTFitsum Tamene
Fitsum Tamene
YJYaming Jiu
Yaming Jiu
RWRigbe G. Weldatsadik
Rigbe G. Weldatsadik
MVMarkku Varjosalo
Markku Varjosalo
Protein-protein interactions govern almost all cellular functions. These complex networks of stable and transient associations can be mapped by affinity purification mass spectrometry (AP-MS) and complementary proximity-based labeling methods such as BioID. To exploit the advantages of both strategies, we here design and optimize an integrated approach combining AP-MS and BioID in a single construct, which we term MAC-tag. We systematically apply the MAC-tag approach to 18 subcellular and 3 sub-organelle localization markers, generating a molecular context database, which can be used to define a protein’s molecular location. In addition, we show that combining the AP-MS and BioID results makes it possible to obtain interaction distances within a protein complex. Taken together, our integrated strategy enables the comprehensive mapping of the physical and functional interactions of proteins, defining their molecular context and improving our understanding of the cellular interactome.

28 October 2021 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
XLXiaonan Liu
Xiaonan Liu
SHSini Huuskonen
Sini Huuskonen
TLTuomo Laitinen
Tuomo Laitinen
TRTaras Redchuk
Taras Redchuk
MBMariia S. Bogacheva
Mariia S. Bogacheva
MVMarkku Varjosalo
Markku Varjosalo
Treatment options for COVID‐19, caused by SARS‐CoV‐2, remain limited. Understanding viral pathogenesis at the molecular level is critical to develop effective therapy. Some recent studies have explored SARS‐CoV‐2–host interactomes and provided great resources for understanding viral replication. However, host proteins that functionally associate with SARS‐CoV‐2 are localized in the corresponding subnetwork within the comprehensive human interactome. Therefore, constructing a downstream network including all potential viral receptors, host cell proteases, and cofactors is necessary and should be used as an additional criterion for the validation of critical host machineries used for viral processing. This study applied both affinity purification mass spectrometry (AP‐MS) and the complementary proximity‐based labeling MS method (BioID‐MS) on 29 viral ORFs and 18 host proteins with potential roles in viral replication to map the interactions relevant to viral processing. The analysis yields a list of 693 hub proteins sharing interactions with both viral baits and host baits and revealed their biological significance for SARS‐CoV‐2. Those hub proteins then served as a rational resource for drug repurposing via a virtual screening approach. The overall process resulted in the suggested repurposing of 59 compounds for 15 protein targets. Furthermore, antiviral effects of some candidate drugs were observed in vitro validation using image‐based drug screen with infectious SARS‐CoV‐2. In addition, our results suggest that the antiviral activity of methotrexate could be associated with its inhibitory effect on specific protein–protein interactions.

10 August 2020 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
XLXiaonan Liu
Xiaonan Liu
KSKari Salokas
Kari Salokas
RWRigbe G. Weldatsadik
Rigbe G. Weldatsadik
LGLisa Gawriyski
Lisa Gawriyski
MVMarkku Varjosalo
Markku Varjosalo

5 April 2022 in EMBO Reports
Verified
Journal Article
Open access
KSKari Salokas
Kari Salokas
XLXiaonan Liu
Xiaonan Liu
TÖTiina Öhman
Tiina Öhman
ICIftekhar Mahmud Chowdhury
Iftekhar Mahmud Chowdhury
LGLisa Gawriyski
Lisa Gawriyski
MVMarkku Varjosalo
Markku Varjosalo
Much cell‐to‐cell communication is facilitated by cell surface receptor tyrosine kinases (RTKs). These proteins phosphorylate their downstream cytoplasmic substrates in response to stimuli such as growth factors. Despite their central roles, the functions of many RTKs are still poorly understood. To resolve the lack of systematic knowledge, we apply three complementary methods to map the molecular context and substrate profiles of RTKs. We use affinity purification coupled to mass spectrometry (AP‐MS) to characterize stable binding partners and RTK–protein complexes, proximity‐dependent biotin identification (BioID) to identify transient and proximal interactions, and an in vitro kinase assay to identify RTK substrates. To identify how kinase interactions depend on kinase activity, we also use kinase‐deficient mutants. Our data represent a comprehensive, systemic mapping of RTK interactions and substrates. This resource adds information regarding well‐studied RTKs, offers insights into the functions of less well‐studied RTKs, and highlights RTK‐RTK interactions and shared signaling pathways.

25 September 2015 in Journal of Computer-Aided Molecular Design
Verified
Journal Article
Closed access
PDF file
SNSanna P. Niinivehmas
Sanna P. Niinivehmas
KSKari Salokas
Kari Salokas
SLSakari Lätti
Sakari Lätti
HRHannu Raunio
Hannu Raunio
OPOlli Pentikäinen
Olli Pentikäinen

8 May 2023 in EMBO Reports
Verified
Journal Article
Open access
LCLarisa Chernyaeva
Larisa Chernyaeva
GRGiorgio Ratti
Giorgio Ratti
LTLaura Teirilä
Laura Teirilä
SFSatoshi Fudo
Satoshi Fudo
URUni Rankka
Uni Rankka
KHKarita Haapasalo
Karita Haapasalo
The APOE4 variant of apolipoprotein E (apoE) is the most prevalent genetic risk allele associated with late‐onset Alzheimer's disease (AD). ApoE interacts with complement regulator factor H (FH), but the role of this interaction in AD pathogenesis is unknown. Here we elucidate the mechanism by which isoform‐specific binding of apoE to FH alters Aβ1‐42‐mediated neurotoxicity and clearance. Flow cytometry and transcriptomic analysis reveal that apoE and FH reduce binding of Aβ1‐42 to complement receptor 3 (CR3) and subsequent phagocytosis by microglia which alters expression of genes involved in AD. Moreover, FH forms complement‐resistant oligomers with apoE/Aβ1‐42 complexes and the formation of these complexes is isoform specific with apoE2 and apoE3 showing higher affinity to FH than apoE4. These FH/apoE complexes reduce Aβ1‐42 oligomerization and toxicity, and colocalize with complement activator C1q deposited on Aβ plaques in the brain. These findings provide an important mechanistic insight into AD pathogenesis and explain how the strongest genetic risk factor for AD predisposes for neuroinflammation in the early stages of the disease pathology.